<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04361513</url>
  </required_header>
  <id_info>
    <org_study_id>28/4/2020</org_study_id>
    <nct_id>NCT04361513</nct_id>
  </id_info>
  <brief_title>Genicular Nerve Block in Rheuamtoid Arthritis</brief_title>
  <official_title>Genicular Nerve Block in Rheumatoid Arthritis: a Prospective Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sohag University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sohag University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      N=64 RA patients either early or established disease diagnosed after ACR/EULAR criteria 2010
      with unilateral persistent knee arthritis. They were randomly assigned into two groups; group
      1 received genicular nerve block, group 2 intra-articular triamcinolone. Both groups were
      examined by SOLAR scoring system, Visual analogue scale (VAS) and Lysholm score at 0, 2 and
      12 weeks. A semi-quantitative score was used to assess tenderness and swelling at the same
      intervals.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 15, 2020</start_date>
  <completion_date type="Actual">July 16, 2020</completion_date>
  <primary_completion_date type="Actual">July 16, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Group received nerve block and another group received steroid</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>The participants does not know the nature of the injected material. Syringe was colored to cover it</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Pain changes by VAS</measure>
    <time_frame>at 0 time after 2 weeks and after 12 weeks</time_frame>
    <description>0 means no pain and 10 means the most severe pain</description>
  </primary_outcome>
  <primary_outcome>
    <measure>SOLAR score for inflammation changes by ultrasound</measure>
    <time_frame>at 0 time after 2 weeks and after 12 weeks</time_frame>
    <description>0 means normal and 27 means the worst possible inflammation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Lysholm score for change in knee function</measure>
    <time_frame>at 0 time after 2 weeks and after 12 weeks</time_frame>
    <description>100 means the best performance and 0 means complete loss of function</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Pain</condition>
  <condition>Joint Function Disorder</condition>
  <condition>Inflammation</condition>
  <arm_group>
    <arm_group_label>Nerve block group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>3 point genicular nerve block under ultrasound guidance. half ml of Bupivacaine hydrochloride 0.5% (Marcaine, Pfizer) was injected in each point.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>intra-articular steroid injection</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>1 mL of triamcinolone 40 milligrams (Kenacort, Bristol Myers Squip) was injected intraarticular.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacaine hydrochloride 0.5% (Marcaine, Pfizer)</intervention_name>
    <description>3 point genicular nerve block</description>
    <arm_group_label>Nerve block group</arm_group_label>
    <arm_group_label>intra-articular steroid injection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>triamcinolone 40 milligrams (Kenacort, Bristol Myers Squip)</intervention_name>
    <description>intra-articular injection of triamcinilone</description>
    <arm_group_label>Nerve block group</arm_group_label>
    <arm_group_label>intra-articular steroid injection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  RA patients

          -  Age &gt; 18

          -  unilateral persistent knee arthritis

        Exclusion Criteria:

          -  Participants with severe knee osteoarthritis

          -  peripheral neuropathy

          -  psoriatic arthritis

          -  skin infection

          -  or those who have allergy for Bupivacaine
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Minia university</name>
      <address>
        <city>Minya</city>
        <zip>82749</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>April 22, 2020</study_first_submitted>
  <study_first_submitted_qc>April 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 24, 2020</study_first_posted>
  <last_update_submitted>July 16, 2020</last_update_submitted>
  <last_update_submitted_qc>July 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sohag University</investigator_affiliation>
    <investigator_full_name>Ahmed Mahrous</investigator_full_name>
    <investigator_title>Associate professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Triamcinolone</mesh_term>
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

